Natasha B Leighl

LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death ...

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025-10

Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-smal...

European journal of cancer (Oxford, England : 1990) · 9 september 2025

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 augustus 2025

Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025-04

NSCLC met driveralteraties: ASCO Living Guideline versie 2025.1

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 december 2024

Subcutaan versus IV amivantamab plus lazertinib bij EGFR-gemuteerd NSCLC: PALOMA-3

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 oktober 2024

NSCLC met driveralteraties: ASCO Living Guideline versie 2024.2

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 juli 2024

NSCLC met driveralteraties: ASCO Living Guideline 2024.1

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 april 2024

NSCLC zonder driveralteraties: ASCO Living Guideline 2024.1

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 april 2024

Pembrolizumab bij NSCLC met hersenmetastasen: IND.227 fase II

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023-06

NSCLC met driveralteraties: ASCO Living Guideline versie 2023.3

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 mei 2023

NSCLC zonder driveralteraties: ASCO Living Guideline versie 2023.3

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 mei 2023

Stadium IV NSCLC zonder driveralteraties: ASCO Living Guideline versie 2023.1

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 februari 2023

Stadium IV NSCLC met driveralteraties: ASCO Living Guideline versie 2023.1

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 februari 2023

Stadium IV NSCLC met driveralteraties: ASCO Living Guideline

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 oktober 2022

Stadium IV NSCLC zonder driveralteraties: ASCO Living Guideline

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 oktober 2022

Durvalumab-tremelimumab met of zonder chemotherapie bij NSCLC: BR34 fase II

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022-03

Nivolumab plus ipilimumab versus nivolumab bij plaveiselcel-NSCLC: Lung-MAP S1400I

JAMA oncology · 1 september 2021

Continue versus 1-jaar nivolumab bij NSCLC: CheckMate 153

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 november 2020

Longkankersurveillance na curatieve therapie: ASCO 2020 richtlijn

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 maart 2020

Brigatinib bij crizotinib-refractair ALK-positief NSCLC: ALTA tweejaars

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2020-03

Moleculaire testrichtlijn voor TKI-selectie bij longkanker: IASLC/ASCO/CAP update

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 maart 2018

Adjuvant chemotherapie met of zonder bevacizumab bij gereseceerd NSCLC: E1505 fase III

The Lancet. Oncology · 2017-12

Nintedanib plus pemetrexed-cisplatine bij maligne pleuramesothelioom: LUME-Meso fase II

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 november 2017

Brigatinib bij crizotinib-refractair ALK-positief NSCLC: ALTA gerandomiseerde fase II-studie

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 augustus 2017

Profylactische huidbehandeling bij EGFR-TKI-geïnduceerde rash: Pan Canadian Rash Trial

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 maart 2016